Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Repayment or prepayment of borrowings
Repaying or prepaying, in full or in part, certain outstanding borrowings availed by the company.
General corporate purposes
The balance of net fresh issue proceeds after the debt repayment object above.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Sai Life Sciences Limited is a contract research, development and manufacturing organisation (CRDMO) that supports biotechnology and pharmaceutical companies across the drug discovery, development and manufacturing value chain. It specialises in small-molecule new chemical entities and provides customised, end-to-end services rather than a single point of the value chain, which lets clients move a molecule from early discovery through commercial-scale manufacturing with one partner. Incorporated in January 1999 and headquartered in Hyderabad, the company operates facilities across India, the United States and the United Kingdom and employs a large scientific workforce of more than 2,300 people. In its most recent full year it served over 280 pharmaceutical innovators, including a majority of the world's largest pharmaceutical companies by revenue, and it has been recognised as one of the fastest-growing listed Indian CRDMOs by revenue and profitability growth in recent years. Growth is supported by a broad and diversified portfolio spanning early discovery projects, late-phase molecules and commercial products, which reduces reliance on any single drug's success. The company's integrated, India-based development and manufacturing model is positioned to benefit from the broader shift of global pharmaceutical outsourcing toward cost-competitive CRDMO partners, while its long-standing relationships with large global pharmaceutical companies support recurring, multi-year engagements.
The company raised about Rs 913 crore from anchor investors ahead of the issue opening, allotting roughly 1.66 crore shares at the upper price band of Rs 549 per share. Participants included Fidelity, BlackRock, the Abu Dhabi Investment Authority, Goldman Sachs, Morgan Stanley, HDFC Mutual Fund, Nippon Life India, Kotak Mahindra AMC, SBI Life Insurance and a broad set of other leading domestic and international mutual funds and insurers.
Source: RHP • Analysis provided for informational purposes
Last Updated: 14 July 2026, 5:30 AM
Integrated CRDMO model
The company offers discovery, development and manufacturing services under one roof, giving clients a single partner across the full drug development lifecycle instead of stitching together multiple vendors.
Established, diversified product portfolio
A portfolio of roughly 50 late-phase and commercial products spreads revenue across many molecules rather than depending on one or two programmes.
Mix of steady and high-potential molecules
The pipeline combines established commercial drugs with under-development molecules that carry meaningful upside if they succeed.
India-based, proximity-led delivery
Running discovery and manufacturing close together in India supports faster iteration and cost efficiency versus a more fragmented global setup.
Broad, high-quality customer base
The company works with a large number of global biotechnology and pharmaceutical companies, including many of the world's largest drugmakers, which supports revenue visibility.
Customer funding and market risk
Revenue depends heavily on biotechnology and pharmaceutical clients, whose spending can be sensitive to their own funding cycles and market conditions.
R&D and project discontinuation risk
Development projects can fail to meet a customer's expectations or be discontinued outright, directly affecting related revenue.
Inherently low drug-development success rates
Most molecules in development never reach commercialisation, which is a structural risk for any CRDMO's future revenue base.
Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Malkajgiri District, Hyderabad-500078
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
International operations risk
Operating facilities and serving clients across multiple countries exposes the company to delays, compliance requirements and other cross-border regulatory challenges.
Loss-making subsidiaries
Certain subsidiaries currently operate at a loss, which can weigh on consolidated profitability until they scale or turn around.
Customer pricing pressure
Large pharmaceutical clients can negotiate hard on pricing, which may compress margins over time.
High working capital intensity
The business ties up significant working capital in ongoing projects and inventory, which can strain liquidity during periods of rapid growth.
No proceeds from the sale portion
The offer-for-sale component of the issue goes entirely to selling shareholders, so it does not fund the company's own operations or growth.